Great news for Repair Biotechnologies a new startup company developing solutions to age-related immune system decline and heart disease.

In 2018, Reason and Bill Cherman founded Repair Biotechnologies, which, as its name suggests, is a rejuvenation biotechnology company focused on damage repair approaches to aging. The company has recently completed a seed round of investment funding, with a total of $2.15 million being put into the company’s coffers to bolster research and development. Reason described this seed round as follows:

We are very pleased to have the support of noted investors such as Jim Mellon. They are the people who are presently providing the fuel and publicity for ever faster progress in the longevity biotechnology industry.

We are also very pleased to have the support of important non-profit organizations such as the SENS Research Foundation. Non-profit groups are just as important as the venture community when it comes to accelerating progress in this field: they are the ones who establish the path and point the way for each new class of therapy.

Non-profit groups are the ones who undertake the hard work of coordinating and funding overlooked research programs in order to create the conditions necessary for venture capital to pay attention to rejuvenation biotechnology.

Longevity companies have often risen and fallen with little ado. But if these financial experts are correct that biotech companies are poised to start “bringing unprecedented increases to the quality and length of human lifespans,” per CNBC, then we may start seeing serious results out of the industry.

“New Frontier”

Bank of America’s predictions would mean a six-fold increase in the amount of money in longevity companies. In a report to clients reviewed by CNBC, analysts wrote that the human lifespan may soon extend to 100 years.